Actively Recruiting

Phase 2
Age: 2Years - 17Years
All Genders
NCT03708900

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Led by RECORDATI GROUP · Updated on 2026-03-27

12

Participants Needed

15

Research Sites

325 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.

CONDITIONS

Official Title

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Who Can Participate

Age: 2Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female children and adolescents from 2 to less than 18 years of age with endogenous Cushing's syndrome who have failed surgery, are awaiting surgery, or for whom surgery is not an immediate option
  • Patients must weigh more than 10 kg
  • Confirmed diagnosis of Cushing's syndrome by clinical signs and specific cortisol tests including dexamethasone suppression test, midnight serum cortisol, or late-night salivary cortisol
  • Able to swallow study drug tablets whole or capsules mixed with water
  • Parents or legal guardians able to provide consent or assent
Not Eligible

You will not qualify if you...

  • Patients with macroadenoma causing or at risk for compressive symptoms needing urgent surgery
  • Insufficient washout period from other cortisol-lowering medications
  • Use of other investigational drugs within 30 days or insufficient washout
  • History of hypersensitivity to osilodrostat or similar drugs
  • History of malignancy within past 5 years, excluding localized basal cell carcinoma
  • Moderate to severe kidney impairment
  • Elevated liver enzymes or bilirubin above specified limits
  • History of thrombosis
  • Risk factors for QTc prolongation or Torsade de Pointes including certain heart conditions and electrolyte imbalances
  • Uncontrolled high blood pressure or hypertension not optimally treated
  • Major surgery within 1 month prior to screening
  • Trans-sphenoidal pituitary surgery within 6 weeks prior to screening unless persistent hypercortisolism
  • Use or anticipated use of systemic glucocorticoids within 1 month prior to screening
  • Uncontrolled hypothyroidism or hyperthyroidism
  • Poorly controlled diabetes or not optimally treated diabetes
  • Positive pregnancy test or pregnancy or nursing in females of childbearing potential
  • Female patients of childbearing potential not agreeing to use highly effective birth control
  • Any medical condition or psychiatric disorder that prevents participation or risks safety
  • Use of prohibited medications during the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

University of California San Francisco UCSF

San Francisco, California, United States, 94143

Actively Recruiting

2

ABMED Clinical Research Corp

Cape Coral, Florida, United States, 33914

Actively Recruiting

3

Ann & Robert H. Lurie Children's Hospital

Chicago, Illinois, United States, 60611

Actively Recruiting

4

National Institute of Child Health and Human Development

Bethesda, Maryland, United States, 20892

Completed

5

Texas Valley Clinical Research

Weslaco, Texas, United States, 78596

Actively Recruiting

6

UZ Brussel

Jette, Brussels Capital, Belgium, 1090

Completed

7

Multiprofile Hospital for Active Treatment Sveta Marina EAD

Varna, Bulgaria, 9010

Withdrawn

8

Hospital Necker Enfants Malades

Paris, France, 75015

Completed

9

Robert Debre Hospital

Paris, France, 75019

Completed

10

CHU Bicetre APHP Paris Saclay

Paris, France, 94270

Completed

11

Aziendal Ospedaliero Universitaria Pisana Presidio Ospedale di Cisanello

Pisa, PI, Italy, 56124

Completed

12

Ospedale Bambino Gesu

Roma, Italy, 00165

Completed

13

University Clinical Center Ljubljana

Ljubljana, Slovenia, 1525

Withdrawn

14

Alder Hey Childrens NHS Foundation Trust

Liverpool, United Kingdom, L12 2AP

Withdrawn

15

The Royal London Childrens Hospital

London, United Kingdom, E11BB

Withdrawn

Loading map...

Research Team

R

Recordati

CONTACT

R

Recordati

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome | DecenTrialz